CelLBxHealth plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANPCY research report →
Companycellbxhealth.com
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology.
- CEO
- Peter Collins
- IPO
- 2015
- Employees
- 119
- HQ
- Guildford, GB
Price Chart
Growth & Income
- Revenue
- $2.86M · 30.92%
- Net Income
- $-14,225,000 · 29.34%
- EPS
- $-0.48 · 37.65%
- Op Income
- $-15,096,000
- FCF YoY
- 8.11%
Performance & Tape
- 52W High
- $2.39
- 52W Low
- $0.07
- 50D MA
- $0.18
- 200D MA
- $0.63
- Beta
- 0.14
- Avg Volume
- 19.15K
Get TickerSpark's AI analysis on ANPCY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ANPCY Coverage
We haven't published any research on ANPCY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ANPCY Report →